Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship

Cancer Research
Sébastien Dall'OzzoGilles Thibault

Abstract

The FCGR3A gene dimorphism generates two allotypes: FcgammaRIIIa-158V and FcgammaRIIIa-158F. The genotype homozygous for FcgammaRIIIa-158V (VV) is associated with higher clinical response to rituximab, a chimeric anti-CD20 IgG1 used in the treatment of B lymphoproliferative malignancies. Our objective was to determine whether this genetic association relates to rituximab-dependent cytotoxicity mediated by FcgammaRIIIa/CD16a+ cells. The number of CD16+ circulating monocytes, T cells, and natural killer (NK) cells in 54 donors was first shown to be unrelated to FCGR3A polymorphism. We then demonstrated that FcgammaRIIIa-158V displays higher affinity for rituximab than FcgammaRIIIa-158F by comparing rituximab concentrations inhibiting the binding of 3G8 mAb (anti-CD16) with VV NK cells and NK cells homozygous for FcgammaRIIIa-158F (FF). VV and FF NK cells killed Daudi cells similarly after FcgammaRIIIa engagement by saturating concentrations of rituximab or 3G8. However, the rituximab concentration resulting in 50% lysis (EC(50)) observed with NK cells from VV donors was 4.2 times lower than that observed with NK cells from FF donors (on average 0.00096 and 0.00402 microg/ml, respectively, P = 0.0043). Finally, the functional diff...Continue Reading

References

Jul 8, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K TobinaiT Murate
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Nov 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BerinsteinD Shen
Jun 29, 1999·Clinical Pharmacokinetics·G AlvánM Wakelkamp
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Feb 7, 2001·Cancer Immunology, Immunotherapy : CII·D ShanO W Press
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Dec 7, 2000·Clinical Pharmacokinetics·H J van den BongardJ H Schellens
Apr 12, 2001·The Journal of Biological Chemistry·S RadaevP D Sun
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Feb 15, 2002·Cancer Immunology, Immunotherapy : CII·Pina M CardarelliGeoffrey Yarranton
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicola Di GaetanoJosée Golay
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy

❮ Previous
Next ❯

Citations

Mar 5, 2008·Cancer Immunology, Immunotherapy : CII·Karl-Johan MalmbergHans-Gustaf Ljunggren
Jun 29, 2011·Cancer Immunology, Immunotherapy : CII·Yoon Kyung JeonSeong Hoe Park
Sep 4, 2009·Annals of Hematology·Andrea BorgerdingLorenz Trümper
Nov 16, 2011·Annals of Hematology·Divi CornecPierre Youinou
Jan 27, 2011·Cancer Metastasis Reviews·Riad Abès, Jean-Luc Teillaud
Feb 14, 2008·Clinical Reviews in Allergy & Immunology·Claudio GalarzaJuan-Manuel Anaya
Jun 10, 2006·Nature Reviews. Drug Discovery·Cecile KrejsaWolfgang Sadee
Feb 9, 2008·Nature Reviews. Drug Discovery·Kresten SkakPallavur V Sivakumar
Feb 2, 2011·Nature Reviews. Drug Discovery·Xu-Rong JiangMark Schenerman
Apr 18, 2007·Nature Reviews. Immunology·Hans-Gustaf Ljunggren, Karl-Johan Malmberg
Jun 11, 2011·Journal of Biomedicine & Biotechnology·Kory L Alderson, Paul M Sondel
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emilian RacilaGeorge J Weiner
Jul 25, 2008·Blood·Michael A Caligiuri
Jan 5, 2013·Journal of Hematology & Oncology·James D MellorAlexander Dobrovic
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L FerrisSoldano Ferrone
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianDrew M Pardoll
Oct 1, 2011·PloS One·Gabriella K BrownGregory M Woods
Nov 19, 2009·Drug Design, Development and Therapy·Akito NatsumeMitsuo Satoh
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
Nov 26, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tadeusz Robak, Ewa Robak
Aug 2, 2011·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Vit ProchazkaKarel Indrak
Oct 24, 2006·Pharmacogenomics·Li Yan, Hugh M Davis
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Greg A LazarBassil I Dahiyat
Sep 19, 2014·Molecular Diagnosis & Therapy·Ksenia Matlawska-WasowskaStuart S Winter
Dec 3, 2013·Nature Chemical Biology·Jason E HudakCarolyn R Bertozzi
Aug 13, 2009·Leukemia & Lymphoma·Guillaume Cartron
Jan 15, 2015·Expert Review of Hematology·Clémentine SarkozyEmmanuel Bachy
Jan 18, 2012·Expert Opinion on Drug Metabolism & Toxicology·Rong DengSuhasini Iyer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.